Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.
This case poses two important questions. First, do schools have the right or the duty to monitor students’ health status measures and require action from parents and, second, what is the role of a student’s primary care physician in this context?
Clarissa G. Barnes, Frederick L. Brancati, MD, MHS, and Tiffany L. Gary, PhD, MHS
To combat the rising incidence of type 2 diabetes, New York City requires laboratories with electronic reporting capacity to upload data on hemoglobin A1c measurements to a city department of health registry.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016;18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.